CN104350054B - 作为选择性细胞周期蛋白依赖性激酶抑制剂的吡唑并三嗪衍生物 - Google Patents

作为选择性细胞周期蛋白依赖性激酶抑制剂的吡唑并三嗪衍生物 Download PDF

Info

Publication number
CN104350054B
CN104350054B CN201380011917.5A CN201380011917A CN104350054B CN 104350054 B CN104350054 B CN 104350054B CN 201380011917 A CN201380011917 A CN 201380011917A CN 104350054 B CN104350054 B CN 104350054B
Authority
CN
China
Prior art keywords
triazine
isopropyls
pyrazolo
bases
benzyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201380011917.5A
Other languages
English (en)
Chinese (zh)
Other versions
CN104350054A (zh
Inventor
J·埃克霍夫
G·齐施因斯基
U·科赫
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Lead Discovery Center GmbH
Original Assignee
Lead Discovery Center GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lead Discovery Center GmbH filed Critical Lead Discovery Center GmbH
Publication of CN104350054A publication Critical patent/CN104350054A/zh
Application granted granted Critical
Publication of CN104350054B publication Critical patent/CN104350054B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems
    • C07D491/107—Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Diabetes (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Cardiology (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Virology (AREA)
  • Rheumatology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Dermatology (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • AIDS & HIV (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
CN201380011917.5A 2012-03-01 2013-03-01 作为选择性细胞周期蛋白依赖性激酶抑制剂的吡唑并三嗪衍生物 Active CN104350054B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP12157751.4 2012-03-01
EP12157751.4A EP2634190A1 (en) 2012-03-01 2012-03-01 Pyrazolo-triazine derivatives as selective cyclin-dependent kinase inhinitors
PCT/EP2013/054224 WO2013128028A1 (en) 2012-03-01 2013-03-01 Pyrazolo - triazine derivatives as selective cyclin- dependent kinase inhinitors

Publications (2)

Publication Number Publication Date
CN104350054A CN104350054A (zh) 2015-02-11
CN104350054B true CN104350054B (zh) 2017-06-13

Family

ID=47757629

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201380011917.5A Active CN104350054B (zh) 2012-03-01 2013-03-01 作为选择性细胞周期蛋白依赖性激酶抑制剂的吡唑并三嗪衍生物

Country Status (17)

Country Link
US (1) US9567345B2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
EP (2) EP2634190A1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
JP (1) JP6182549B2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
KR (1) KR101821452B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
CN (1) CN104350054B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
AU (1) AU2013224848B2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
BR (1) BR112014021189B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
CA (1) CA2865946C (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
DK (1) DK2820020T3 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
ES (1) ES2583231T3 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
HU (1) HUE029264T2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
IL (1) IL234183A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
MX (1) MX347359B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
RU (1) RU2645347C2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
SG (1) SG11201405129RA (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
WO (1) WO2013128028A1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
ZA (1) ZA201406078B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA119247C2 (uk) 2013-09-06 2019-05-27 РОЙВЕНТ САЙЕНСИЗ ҐмбГ Спіроциклічні сполуки як інгібітори триптофангідроксилази
GB201403093D0 (en) 2014-02-21 2014-04-09 Cancer Rec Tech Ltd Therapeutic compounds and their use
EP3489232A3 (en) 2014-04-04 2019-07-31 Syros Pharmaceuticals, Inc. Inhibitors of cyclin-dependent kinase 7 (cdk7)
EP3129371B1 (en) 2014-04-05 2020-07-29 Syros Pharmaceuticals, Inc. Inhibitors of cyclin-dependent kinase 7 (cdk7)
AU2015337607B2 (en) 2014-10-31 2020-04-09 Ube Corporation Substituted dihydropyrrolopyrazole compound
WO2016142855A2 (en) * 2015-03-09 2016-09-15 Aurigene Discovery Technologies Limited Pyrazolo[1,5-a][1,3,5]triazine and pyrazolo[1,5-a]pyrimidine derivatives as cdk inhibitors
CA2989519C (en) 2015-06-15 2023-09-26 Ube Industries, Ltd. Substituted dihydropyrrolopyrazole derivative
US10407429B2 (en) * 2015-06-24 2019-09-10 Curovir Ab Pyrazolo[1,5-a]triazin-4-amine derivatives useful in therapy
AU2017326253B2 (en) 2016-09-13 2021-10-21 Allergan, Inc. Stabilized non-protein clostridial toxin compositions
CN106432249B (zh) * 2016-09-30 2018-12-04 陕西科技大学 一类吡咯并[2，1-f][1，2，4]三嗪母核化合物的合成及其医药用途
US11345705B2 (en) 2017-08-09 2022-05-31 Sanford Burnham Prebys Medical Discovery Institute Substituted pyrazolo[1,5-a]pyrimidines as apelin receptor agonists
GB201715194D0 (en) 2017-09-20 2017-11-01 Carrick Therapeutics Ltd Compounds and their therapeutic use
TWI795510B (zh) * 2018-01-17 2023-03-11 英商葛蘭素史密斯克藍智慧財產發展有限公司 PI4KIIIβ抑制劑
AU2019250507B2 (en) * 2018-04-11 2023-09-28 Lead Discovery Center Gmbh Pyrazolo-triazine and/or pyrazolo-pyrimidine derivatives as selective inhibitor of cyclin dependent kinase
MY207194A (en) * 2018-04-11 2025-02-05 Qurient Co Ltd Pharmaceutically active pyrazolo-triazine and/or pyrazolo-pyrimidine derivatives
US11517568B2 (en) 2018-09-12 2022-12-06 The Governing Council Of The University Of Toronto Compounds and methods for treating nematode infections
US12022832B2 (en) 2018-09-12 2024-07-02 The Governing Council Of The University Of Toronto Compounds and methods for treating nematode infections
WO2020093011A1 (en) 2018-11-01 2020-05-07 Syros Pharmaceuticals, Inc. Inhibitors of cyclin-dependent kinase 7 (cdk7)
WO2020100944A1 (ja) 2018-11-14 2020-05-22 宇部興産株式会社 ジヒドロピロロピラゾール誘導体
CN110101703B (zh) * 2019-05-06 2021-06-11 暨南大学 Cdk7抑制剂在制备溃疡性结肠炎或结肠癌药物的应用
RU2713152C1 (ru) * 2019-08-30 2020-02-04 Федеральное государственное бюджетное образовательное учреждение высшего образования "Алтайский государственный медицинский университет" Министерства здравоохранения Российской Федерации Способ лечения хронической аллергической крапивницы на фоне описторхоза
TW202146416A (zh) * 2019-12-11 2021-12-16 德商拜耳廠股份有限公司 吡唑并三𠯤
GB201918541D0 (en) * 2019-12-16 2020-01-29 Carrick Therapeutics Ltd Therapeutic compounds and their use
CN110950871B (zh) * 2019-12-25 2022-05-17 陕西师范大学 2-取代-4-芳氨基吡唑并三嗪衍生物及制备抗肿瘤药物的应用
CN116964061A (zh) * 2020-12-21 2023-10-27 詹森药业有限公司 作为细胞周期蛋白依赖性激酶7（cdk7）抑制剂的三环嘧啶
JP2024509864A (ja) * 2021-03-09 2024-03-05 ヤンセン ファーマシューティカ エヌ．ベー． サイクリン依存性キナーゼ７（ｃｄｋ７）阻害剤としての三環式ピリジン
WO2022266418A1 (en) * 2021-06-17 2022-12-22 H. Lee Moffitt Cancer Center And Research Institute, Inc. Triazine inhibitors of cyclin-dependent kinases
WO2023001061A1 (en) * 2021-07-17 2023-01-26 Jingrui Biopharma Co., Ltd. Cdk7 selective inhibitors as anticancer agents
US20240327397A1 (en) 2021-07-29 2024-10-03 Syngenta Crop Protection Ag Pesticidally Active Fused Bicyclic Heteroaromatic Compounds
JP2024541474A (ja) * 2021-11-23 2024-11-08 オリゲニス ゲーエムベーハー Ｃｄｋ９阻害剤として有用なピラゾロトリアジン誘導体
CN114181217B (zh) * 2022-01-10 2022-12-27 陕西师范大学 吡唑并[1,5-a][1,3,5]三嗪衍生物及其盐和在制备抗癌药物中的应用
IL315338A (en) * 2022-03-18 2024-10-01 Qurient Co Ltd Cdk7 inhibitors for antiviral treatment
CN120712267A (zh) * 2023-02-21 2025-09-26 杭州德睿智药科技有限公司 作为CDKs抑制剂的新型并杂环类新化合物及其应用

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005077954A2 (en) * 2004-02-11 2005-08-25 Schering Corporation Pyrazolopyrimidine-derivatives as cyclin dependent kinase inhibitors
CN1922185A (zh) * 2004-02-25 2007-02-28 先灵公司 作为激酶抑制剂的吡唑并三嗪类化合物
WO2010103486A1 (fr) * 2009-03-11 2010-09-16 Centre National De La Recherche Scientifique Derives de pyrazolo[1,5-a]-1,3,5-triazines, leur preparation et leur application en therapeutique

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US615968A (en) 1898-12-13 Apparatus for treating ores
PL350001A1 (en) * 1999-02-01 2002-10-21 Cv Therapeutics Purine inhibitors of cyclin dependent kinase 2 and iκ-aα
CZ302122B6 (cs) * 2009-01-28 2010-10-20 Univerzita Palackého v Olomouci Substituované deriváty 6-(2-aminobenzylamino)purinu, jejich použití jako léciva a prípravky tyto slouceniny obsahující
CZ302711B6 (cs) * 2009-06-03 2011-09-14 Univerzita Palackého v Olomouci Substituované deriváty 6-(2-hydroxybenzylamino)purinu, jejich použití jako léciva a farmaceutické prípravky tyto slouceniny obsahující

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005077954A2 (en) * 2004-02-11 2005-08-25 Schering Corporation Pyrazolopyrimidine-derivatives as cyclin dependent kinase inhibitors
CN1922185A (zh) * 2004-02-25 2007-02-28 先灵公司 作为激酶抑制剂的吡唑并三嗪类化合物
WO2010103486A1 (fr) * 2009-03-11 2010-09-16 Centre National De La Recherche Scientifique Derives de pyrazolo[1,5-a]-1,3,5-triazines, leur preparation et leur application en therapeutique

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
Pyrazolo[1,5-a]-1,3,5-triazine as a Purine Bioisostere: Access to Potent Cyclin-Dependent Kinase Inhibitor (R)-Roscovitine Analogue;Florence Popowycz，等;《Journal of Medicinal Chemistry》;20090701;第52卷(第3期);第655-663页 *
Synthesis and antiproliferative evaluation of pyrazolo[1,5-a]-1,3,5-triazine myoseverin derivatives;Florence Popowycz，等;《Bioorganic & Medicinal Chemistry》;20090310;第17卷(第9期);第3471-3478页 *

Also Published As

Publication number Publication date
RU2014139705A (ru) 2016-04-20
ES2583231T3 (es) 2016-09-19
BR112014021189B1 (pt) 2022-08-16
AU2013224848B2 (en) 2017-06-29
HUE029264T2 (en) 2017-02-28
HK1206014A1 (en) 2015-12-31
CN104350054A (zh) 2015-02-11
KR101821452B1 (ko) 2018-01-23
ZA201406078B (en) 2016-08-31
BR112014021189A2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) 2017-06-20
EP2634190A1 (en) 2013-09-04
US20150018329A1 (en) 2015-01-15
EP2820020A1 (en) 2015-01-07
MX347359B (es) 2017-04-06
JP6182549B2 (ja) 2017-08-16
SG11201405129RA (en) 2014-09-26
DK2820020T3 (en) 2016-07-04
AU2013224848A1 (en) 2014-08-28
EP2820020B1 (en) 2016-04-06
CA2865946A1 (en) 2013-09-06
MX2014010494A (es) 2015-04-08
WO2013128028A1 (en) 2013-09-06
KR20140131994A (ko) 2014-11-14
IL234183A (en) 2016-11-30
US9567345B2 (en) 2017-02-14
CA2865946C (en) 2020-01-21
RU2645347C2 (ru) 2018-02-21
WO2013128028A8 (en) 2014-10-02
JP2015511952A (ja) 2015-04-23

Similar Documents

Publication Publication Date Title
CN104350054B (zh) 作为选择性细胞周期蛋白依赖性激酶抑制剂的吡唑并三嗪衍生物
US9096608B2 (en) Pharmaceutically active pyrazolo-triazine derivatives
CN103492370B (zh) 取代的二氨基甲酰胺和二氨基甲腈嘧啶，其组合物，和用其治疗的方法
CN103562184A (zh) 药学活性的二取代的吡啶衍生物
SA111320281B1 (ar) مشتقات ترايازين مستبدلة ثنائيا ونشطة دوائيا
CN106459084B (zh) 大环化合物
TW200813013A (en) N-(amino-heteroaryl)-1H-indole-2-carboxamide derivatives, preparation thereof and therapeutic use thereof
TW200906394A (en) Tetrahydroindole and tetrahydroindazole derivatives
US11008335B2 (en) Positive allosteric modulators of the muscarinic acetylcholine receptor M4
CN100439365C (zh) 用作蛋白激酶抑制剂的化合物和组合物
TW200413385A (en) Condensed furan compounds
WO2004111003A1 (en) Amide derivatives as selective serotonin re-uptake inhibitors
TW200304817A (en) Chemical compounds
WO2019085895A1 (zh) 一类氨基取代含氮稠环化合物及其制备方法和用途
WO2022105526A1 (zh) 二氢异喹啉酮和异吲哚啉酮衍生物及其用途
TW200536843A (en) Heterocyclic compound
CN106414412B (zh) 含有磺酰二亚胺基团的二取代的5-氟嘧啶衍生物
US20200323857A1 (en) Positive allosteric modulators of the muscarinic acetylcholine receptor m4
CN106470974B (zh) 用于治疗病毒感染的化合物
CN109942544A (zh) 一类新型吲唑类衍生物激酶抑制剂
CN106749203A (zh) 一种嘧啶类杂环化合物、嘧啶类杂环化合物盐以及制备方法和应用
HK1206014B (en) Pyrazolo-triazine derivatives as selective cyclin-dependent kinase inhinitors
TWI291960B (en) Pyrimidine compounds of formula (ι),and pharmaceutical composition having cell-cycle inhibitory activity comprising the
EA046684B1 (ru) Гетероароматические соединения в качестве ингибиторов ванина
CN101146797A (zh) 用于治疗炎性疾病的作为p38map-激酶抑制剂的4-′2-(环烷基氨基)嘧啶-4-yl！-3-(苯基)-咪唑啉-2-酮衍生物

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1206014

Country of ref document: HK

GR01 Patent grant
GR01 Patent grant
REG Reference to a national code

Ref country code: HK

Ref legal event code: GR

Ref document number: 1206014

Country of ref document: HK